Hunan Jingfeng Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2019
April 24, 2019 at 02:03 pm EDT
Share
Hunan Jingfeng Pharmaceutical Co.,Ltd. announced earnings results for the first quarter ended March 31, 2019. For the first quarter, the company announced sales was CNY 294.625 million compared to CNY 382.981 million a year ago. Operating income was CNY 13.081 million compared to CNY 28.425 million a year ago. Net income was CNY 19.196 million compared to CNY 15.134 million a year ago. Basic earnings per share from continuing operations was CNY 0.0218 compared to CNY 0.0172 a year ago.
Hunan Jingfeng Pharmaceutical Co.,Ltd., formerly Hunan Tianyi Science and Technology Co., Ltd, is a China-based company principally engaged in the research, development, manufacture and sale of chemical drugs, biochemical drugs and traditional Chinese patent drugs. The Company's main products includes cardio and cerebrovascular drugs, antihypertensive and hypolipidemic drugs, orthopedic drugs, anti-tumor products, endocrine drugs, digestive system drugs, antiviral drugs and anti-infective drugs, among others. The Company is also involved in commodity import and export trading, business management and consulting, as well as medical technology consulting business. The Company distributes its products in the domestic market.
HUNAN JINGFENG PHARMACEUTICAL CO.,LTD. 
